<DOC>
	<DOCNO>NCT01652092</DOCNO>
	<brief_summary>This standard care treatment guideline allogeneic hematopoetic stem cell transplant ( HSCT ) patient primary immune deficiency .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplant Patients With Primary Immune Deficiencies</brief_title>
	<detailed_description>Based diagnosis clinical history , determination appropriate regimen make base follow prep plan : Arm A : Fully Myeloablative Preparative Regimen , Arm B : Reduced Toxicity Ablative Preparative Regimen , Arm C : Reduced Intensity Conditioning , Arm D : No Preparative Regimen</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome , Type 1</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Diagnosis immunodeficiency histiocytic disorder include follow : Severe combine immunodeficiency ( SCID variant ) Second bone marrow transplant ( BMT ) SCID ( graft rejection ) Omenn 's Syndrome Reticular dysgenesis WiskottAldrich syndrome Major histocompatibility complex ( MHC ) Class II deficiency ( bare lymphocyte syndrome ) Hyper IgM Syndrome ( CD40 Ligand Deficiency ) Common variable immunodeficiency ( CVID ) severe phenotype Chronic Granulomatous Disease ( CGD ) Other severe Combined Immune Deficiencies ( CID ) Hemophagocytic Lymphohistiocytosis ( HLH ) Xlinked Lymphoproliferative Disease ( XLP ) ChediakHigashi Syndrome ( CHS ) Griscelli Syndrome Langerhans Cell Histiocytosis ( LCH ) Acceptable stem cell source include : HLA identical 1 antigen match sibling donor eligible donate bone marrow HLA identical 1 antigen mismatch unrelated BM donor Sibling donor cord blood acceptable HLA match cell dose per current institutional standard Single unrelated umbilical cord blood unit 02 antigen mismatch minimum cell dose &gt; 5 x 10^7 nucleated cells/kg per current institutional guideline Double unrelated umbilical cord blood unit : 2 antigen mismatch patient 2 antigen mismatch minimum cell dose least one single unit must ≥ 3.5 x 10^7 nucleated cells/kg combine dose unit must provide total cell dose ≥ 5 x 10^7 nucleated cells/kg Age : 0 50 year Adequate organ function performance status . Exclusion Criteria pregnant breastfeeding active , uncontrolled infection and/or HIV positive acute hepatitis evidence moderate severe portal fibrosis cirrhosis biopsy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>immunodeficiency disorder</keyword>
	<keyword>histiocytic disorder</keyword>
</DOC>